A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Trial details
- Registry ID
- NCT07771465
- Drugs studied
- Danicamtiv
TrialRedline tracks 5 clinical trials sponsored by Kardigan, Inc.: 1 Phase 3, 2 Phase 2 / 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated CardiomyopathyNCT07771465 | Danicamtiv | Recruiting | 2032-11Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled StudyNCT07001800 | Ataciguat | Recruiting | 2028-08-31Estimated |
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated CardiomyopathyNCT07210723 | danicamtiv | Recruiting | 2027-09Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe HypertensionNCT07511361 | Tonlamarsen | Recruiting | 2026-12Estimated |
| A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)NCT06864104 | Tonlamarsen | Completed | 2026-01-12Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels Measure: To assess the systolic blood pressure-lowering effect of tonlamarsen. After: Measure: Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions Measure: Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels.
Before: 100 participants (planned). After: 140 participants (planned).
Before: 29 Dec 2026. After: Dec 2026.
Before: Not yet recruiting. After: Recruiting.
NCT06864104 · Kardigan, Inc.
Before: Active not recruiting. After: Completed.
NCT06864104 · Kardigan, Inc.
Before: Estimated. After: Actual.
Before: 9 Jan 2026. After: 12 Jan 2026.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: (Part A) Change in Aortic Valve Calcium (AVC) from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in AVA as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 from baseline to Week 48. After: Measure: (Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48.
Before: 1410 participants (planned). After: 1276 participants (planned).
Before: PHASE3. After: PHASE2, PHASE3.